LitAlert ~~ GeneLit.com

    • Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM
    • Renault AL, Dowty JG, Steen JA, Li S, Winship IM, Giles GG, Hopper JL, Southey MC, Nguyen-Dumont T.
    • Breast Cancer Res. 2022 Apr 1;24(1):24. doi: 10.1186/s13058-022-01518-y.
    • Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    • Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE,, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NU.
    • Clin Cancer Res. 2022 Apr 1:clincanres.2861.2021. doi: 10.1158/1078-0432.CCR-21-2861. Epub ahead of print.
    • Immunotherapy for Ovarian Cancer.
    • Porter R, Matulonis UA.
    • Clin Adv Hematol Oncol. 2022 Apr;20(4):240-253.
    • Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
    • Armstrong AJ.
    • Clin Adv Hematol Oncol. 2022 Apr;20 Suppl 8(4):1-23.

    Review:

    Phase 3 MAGNITUDE Study: First Results of Niraparib With Abiraterone Acetate and Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With and Without Homologous Recombination Repair Gene Alterations.

    Review:

    PROpel: Phase III Trial of Olaparib and Abiraterone vs Placebo and Abiraterone as First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

    Commentary:

    Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.

    • Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
    • Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K.
    • Asia Pac J Clin Oncol. 2022 Mar 31. doi: 10.1111/ajco.13753. Epub ahead of print.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Mar 31:clincanres.0442.2022. doi: 10.1158/1078-0432.CCR-22-0442. Epub ahead of print.
    • Commentary